Results 21 to 30 of about 1,629 (148)
Blastic plasmacytoid dendritic cell neoplasm is an aggressive malignancy derived from plasmacytoid dendritic cells. There is currently no accepted standard of care for treating this neoplasm, and therapeutic strategies have never been prospectively ...
Fanny Angelot-Delettre +20 more
doaj +1 more source
Bortezomib as a new therapeutic approach for blastic plasmacytoid dendritic cell neoplasm
Blastic plasmacytoid dendritic cell neoplasm is an aggressive hematologic malignancy with a poor prognosis. No consensus regarding optimal treatment modalities is currently available. Targeting the nuclear factor-kappa B pathway is considered a promising
Laure Philippe +11 more
doaj +1 more source
MRD IN BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM
Objective: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an extremely rare disease with an aggressive course. Plasmacytoid dendritic cells (PDCs) are a component of the innate immune response: they secrete large amounts of type I interferons ...
Aleksandra Palladina +3 more
doaj +1 more source
Cytoplasmic nucleophosmin is not detected in blastic plasmacytoid dendritic cell neoplasm
Acute myeloid leukemia carrying cytoplasmic mutated nucleophosmin (NPMc+ AML) and blastic plasmacytoid dendritic cell neoplasm have been included as new entities in the 4th edition (2008) WHO classification of myeloid neoplasms. These conditions may show
Fabio Facchetti +7 more
doaj +1 more source
Treatment of blastic plasmacytoid dendritic cell neoplasm [PDF]
Abstract Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare myeloid malignancy with no defined standard of care. BPDCN presents most commonly with skin lesions with or without extramedullary organ involvement before leukemic dissemination.
Jill M, Sullivan, David A, Rizzieri
openaire +2 more sources
A Case of Blastic Plasmacytoid Dendritic Cell Neoplasm [PDF]
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, highly aggressive hematopoietic malignancy that is characterized by cutaneous and bone marrow involvement and leukemic spread, representing 0.7% of primary cutaneous lymphomas1. Formerly known as CD4+/CD56+ hematodermic neoplasm or blastic NK-cell lymphoma2, BPDCN is derived from ...
Pinto-Almeida, Teresa +6 more
openaire +2 more sources
Background We describe a patient with blastic plasmacytoid dendritic cell neoplasm with central nervous system involvement and the outcome of venetoclax use in this setting.
Nil Albiol +5 more
doaj +1 more source
Blastic plasmacytoid dendritic cell neoplasm of the uterus [PDF]
Introduction. Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and very aggressive hematological malignancy derived from precursor of the plasmacytoid dendritic cell.
Đurđević Predrag +8 more
doaj +1 more source
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive hematodermic malignancy derived from plasmacytoid dendritic cell precursors. Despite advances in our understanding of tumor cell surface markers, the pathogenesis of BPDCN remains
Xinmei Dang +3 more
doaj +1 more source
Disseminated blastic plasmacytoid dendritic cell neoplasm [PDF]
![Figure][1] A 63-year-old man presented with cutaneous nodules. Workup revealed anemia, thrombocytopenia, monocytosis, and 5% circulating “blasts.” Bone marrow sampling showed 33% immature-appearing cells (panel A), with occasional “tadpole” appearance (panel A, lower inset) and ...
Sanam Loghavi, Joseph D. Khoury
openaire +2 more sources

